Coherus Biosciences Inc (CHRS)

Apr 17, 2025

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs - Seeking Alpha

Apr 17, 2025

Apr 16, 2025

Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment - insights.citeline.com

Apr 16, 2025

Apr 15, 2025

Coherus divests Udenyca franchise to Intas for up to $558.4m - MSN

Apr 15, 2025

Apr 15, 2025

Latham & Watkins Assists Coherus BioSciences in Obtaining CFIUS Clearance - Latham & Watkins LLP

Apr 15, 2025

Apr 15, 2025

Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals

Apr 15, 2025

Apr 15, 2025

Intas acquires Neulasta biosimilar Udenyca from Coherus BioSciences - World Pharmaceutical Frontiers

Apr 15, 2025

Apr 15, 2025

Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals

Apr 15, 2025

Apr 14, 2025

Coherus BioSciences (CHRS) Completes Divestiture of UDENYCA Fran - GuruFocus

Apr 14, 2025

Apr 14, 2025

Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Coherus completes strategic transformation - The Pharma Letter

Apr 14, 2025

Apr 14, 2025

Accord Biopharma Announces Completion Of Udenyca(Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus Biosciences, Inc., Expanding U.S. Biosimilar Portfolio - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Intas Pharmaceuticals Acquires UDENYCA Business from Coherus BioSciences - Contract Pharma

Apr 14, 2025

Apr 14, 2025

Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio - PR Newswire

Apr 14, 2025

Apr 14, 2025

Coherus Biosciences Completes UDENYCA Franchise Divestiture - TipRanks

Apr 14, 2025

Apr 14, 2025

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise - GlobeNewswire

Apr 14, 2025

Apr 14, 2025

Coherus Lands Massive $558M Deal: Strategic Pivot to Oncology Extends Cash Runway to 2027 - Stock Titan

Apr 14, 2025

Apr 01, 2025

Coherus BioSciences to Repurchase $170 Million Convertible Notes - MarketScreener

Apr 01, 2025

Apr 01, 2025

Coherus BioSciences to repurchase $170 million in convertible notes - Investing.com India

Apr 01, 2025

Apr 01, 2025

Coherus BioSciences To Buy Back $170 Mln Of 1.500% Convertible Sr. Subordinated Notes - Nasdaq

Apr 01, 2025

Apr 01, 2025

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes - Bluefield Daily Telegraph

Apr 01, 2025

Apr 01, 2025

Coherus Unveils Massive $230M Debt Reduction Plan, Starting With $170M Note Buyback - Stock Titan

Apr 01, 2025

Mar 28, 2025

Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop - simplywall.st

Mar 28, 2025

Mar 27, 2025

Coherus BioSciences : Block Advisors by H&R Block to Provide Timely Support for The Home Depot’s Pro Xtra Loyalty Members - MarketScreener

Mar 27, 2025

Mar 25, 2025

Coherus to Present Data from a Phase 1 Dose Expansion Study - GlobeNewswire

Mar 25, 2025

Mar 25, 2025

Breakthrough Cancer Treatment Data: Coherus' CCR8 Antibody Shows Promise in Head & Neck Cancer Trial - Stock Titan

Mar 25, 2025

Mar 24, 2025

Lobbying Update: $65,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Nasdaq

Mar 24, 2025

Mar 24, 2025

Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings - simplywall.st

Mar 24, 2025

Mar 24, 2025

Statutory Earnings May Not Be The Best Way To Understand Coherus BioSciences' (NASDAQ:CHRS) True Position - Yahoo Finance

Mar 24, 2025

Mar 17, 2025

Coherus BioSciences, Inc. SEC 10-K Report - TradingView

Mar 17, 2025

Mar 14, 2025

Coherus BioSciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 14, 2025

Mar 13, 2025

Coherus BioSciences Shareholders Approve UDENYCA Franchise Sale By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Coherus Prepares To Wave Goodbye To Udenyca – And 30% Of Its Staff - insights.citeline.com

Mar 13, 2025

Mar 13, 2025

Coherus BioSciences Shareholders Approve UDENYCA Franchise Sale - Investing.com India

Mar 13, 2025

Mar 12, 2025

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Insider Monkey

Mar 12, 2025

Mar 12, 2025

Coherus BioSciences (NASDAQ:CHRS) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 12, 2025

Mar 11, 2025

Coherus BioSciences’ Earnings Call: Growth and Challenges - TipRanks

Mar 11, 2025

Mar 11, 2025

Coherus Biosciences: Strategic Divestment and Pipeline Focus Justify Buy Rating - TipRanks

Mar 11, 2025

Mar 11, 2025

Coherus stock rating upgraded on Loqtorzi sales growth By Investing.com - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Coherus stock rating upgraded on Loqtorzi sales growth - Investing.com

Mar 11, 2025

Mar 11, 2025

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 11, 2025

Mar 11, 2025

Earnings call transcript: Coherus BioSciences Q4 2024 sees revenue beat By Investing.com - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Mar 11, 2025

Mar 11, 2025

Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Transition - GuruFocus.com

Mar 11, 2025

Mar 10, 2025

Coherus BioSciences: Q4 Earnings Snapshot - The Washington Post

Mar 10, 2025

Mar 10, 2025

Coherus BioSciences earnings beat by $0.02, revenue topped estimates - Investing.com Canada

Mar 10, 2025

Mar 10, 2025

Earnings call transcript: Coherus BioSciences Q4 2024 sees revenue beat - Investing.com India

Mar 10, 2025

Mar 10, 2025

Coherus BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 10, 2025

Mar 10, 2025

Coherus Biosciences, Inc. Q4 Loss Narrows - Nasdaq

Mar 10, 2025